Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
46.6M
-
Shares change
-
+7.78M
-
Total reported value, excl. options
-
$90.9M
-
Value change
-
+$6.16M
-
Put/Call ratio
-
16.86
-
Number of buys
-
37
-
Number of sells
-
-26
-
Price
-
$1.95
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q1 2023
75 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q1 2023.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.6M shares
of 112M outstanding shares and own 41.65% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13.6M shares), CITADEL ADVISORS LLC (3.37M shares), Prosight Management, LP (3.26M shares), JPMORGAN CHASE & CO (3.09M shares), GOLDMAN SACHS GROUP INC (2.35M shares), Sio Capital Management, LLC (2.16M shares), MILLENNIUM MANAGEMENT LLC (1.79M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.68M shares), Frazier Life Sciences Management, L.P. (1.65M shares), and BANK OF AMERICA CORP /DE/ (1.64M shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.